N/A
Completed N=70
The Development of a Mobile-based App to Increase Uptake of Pre-Exposure Prophylaxis (PrEP) by Men Who Have Sex With Men in China
HIV · Pre-exposure Prophylaxis
Source: ClinicalTrials.gov NCT04426656 ↗
Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcomePrimary: Change in Intention to Use PrEP Score — 0.19; 0.00; 0.57; -0.09 score on a scale — p=0.85
Summary
This study aims to use a mini-application on the popular Chinese social media mobile platform, WeChat, to improve HIV pre-exposure prophylaxis (PrEP) uptake among at-risk men who have sex with men (MSM). UNC investigators will work in close partnership with a well-established HIV special hospital and the local MSM community to understand key barriers to PrEP use, and develop a mobile-based intervention to increase PrEP uptake among young MSM in Guangzhou, China.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Intention to Use PrEP Score |
0.19; 0.00; 0.57; -0.09; 1.00; -0.40 | 0.85 |
| PRIMARY Number of Participants Who Initiate PrEP by Week 8 |
5; 8 | 0.72 |
| PRIMARY Number of Participants at Different Change Stages to PrEP Initiation at Baseline |
9; 15; 8; 24; 4; 4 | 0.318 |
| PRIMARY Number of Participants at Different Change Stages to PrEP Initiation at Week 4 |
10; 15; 5; 12; 6; 12 | 0.527 |
| PRIMARY Number of Participants at Different Change Stages to PrEP Initiation at Week 8 |
8; 20; 4; 7; 4; 8 | 0.928 |
| PRIMARY Number of Participants at Different Change Stages to PrEP Initiation at Week 12 |
8; 17; 3; 11; 5; 7 | 0.678 |
| SECONDARY Change in PrEP Knowledge Score at Week 4, 8 and 12 |
0.33; 0.13; 0.33; 0.16; 0.38; 0.19 | 0.26 |
| SECONDARY Number of Participants Who Are Willing to Pay a Specified Percentage of Monthly Income for PrEP |
0; 6; 0; 0; 0; 4 | 0.08 |
| SECONDARY Change in PrEP Self-Efficacy Score |
0.05; 0.07; 0.08; 0.03; 0.10; 0.13 | 0.03 sig |
| SECONDARY Change in PrEP Attitude Score |
0.06; 0.07; 0.23; 0.01; 0.02; 0.02 | 0.58 |
| SECONDARY Change in PrEP Stigma Score |
0.06; -0.02; 0.23; 0.09; 0.02; 0.03 | 0.85 |
| SECONDARY Number of Participants Who Ordered At-home HIV/Syphilis Tests |
13 | — |
Eligibility Criteria
Inclusion Criteria
- Part 1: HIV-negative men who have sex with men (MSM): must self-report: being assigned male sex at birth, HIV-negative, age 18 and above, ever having had anal sex with another man, identify as a Chinese citizen, own a smartphone, able to being willing to sign written informed consent and participate in the study as procedures required.
Part 2: HIV-negative men who have sex with men (MSM): same characteristics as in Part 1.
AND, they must report :
- Having a smartphone with WeChat installed.
- Being assigned male sex at birth, HIV-negative, age 18 and above, ever having had anal sex with another man, currently reside in Guangzhou, China, identifying as a Chinese citizen, able to sign written informed consent and participate in the study as procedures require. AND
- At least one criterion associated with high risk of HIV infection in the past 6 months prior to enrollment as follows:
- Unprotected (condomless) anal intercourse with male partner(s)
- More than two male partners (regardless of condom use and HIV serostatus)
- Reported STI, such as syphilis, Herpes Simplex Virus-2 (HSV-2), gonorrhea, chlamydia, chancroid, or lymphogranuloma venereum.
- Reported use of post-exposure prophylaxis (PEP)
- Have a sexual partner living with HIV
Exclusion Criteria
- Part 1: Individuals who report any following status will be excluded from participating Part 1:
- HIV-positive
- Mental health issues which may compromise participant adherence or safety, including memory loss, cognitive impairment, intellectual disability, or communication disorders.
- Part 2:
- HIV-positive (self-report or lab-confirmed)
- Currently taking oral PrEP based on self-report
- Symptoms of acute HIV infection within the prior 30 days
- Contradictions to taking oral PrEP
- Personal diagnosis or family history of hemophilia
- Chronic Hepatitis B (self-report)
- Participating in another research study related to HIV and antiretroviral therapy or other intervention study
- Having serious chronic disease, including metabolic diseases (such as diabetes), neurological, and psychiatric disorders
- Mental health issues which may compromise participant adherence or safety, including memory loss, cognitive impairment, intellectual disability, or communication disorders
Data sourced from ClinicalTrials.gov (NCT04426656). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.